Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
Jacek Mackiewicz, Andrzej Maćkiewicz
Współczesna Onkologia (2018) Vol. 2018, Iss. 1, pp. 68-72
Open Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

Targeted Therapy in Melanoma and Mechanisms of Resistance
Anna M. Czarnecka, Ewa Bartnik, Michał Fiedorowicz, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 13, pp. 4576-4576
Open Access | Times Cited: 143
Melanoma Management: From Epidemiology to Treatment and Latest Advances
Joana Lopes, Cecília M. P. Rodrigues, Maria Manuela Gaspar, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4652-4652
Open Access | Times Cited: 92
Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts
Victoria Dunnett-Kane, Emma Burkitt‐Wright, Fiona Blackhall, et al.
Annals of Oncology (2020) Vol. 31, Iss. 7, pp. 873-883
Open Access | Times Cited: 53
Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
Andrew Patterson, Noam Auslander
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 28
Canine melanoma: A review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies
Valentina B. Stevenson, Shawna Klahn, Tanya LeRoith, et al.
Frontiers in Veterinary Science (2023) Vol. 9
Open Access | Times Cited: 19
Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer
Marco Rubatto, Nadia Sciamarrelli, Silvia Borriello, et al.
Frontiers in Medicine (2023) Vol. 9
Open Access | Times Cited: 18
Synthetic Approaches to New Drugs Approved During 2016
Andrew C. Flick, Hong X. Ding, Carolyn A. Leverett, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 16, pp. 7004-7031
Closed Access | Times Cited: 56
Nanodelivery systems for cutaneous melanoma treatment
Irina Pereira, Carina Monteiro, Miguel Pereira‐Silva, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2023) Vol. 184, pp. 214-247
Open Access | Times Cited: 15
Functionalization of Nanomaterials and Their Application in Melanoma Cancer Theranostics
Vijay Sagar Madamsetty, Manash K. Paul, Anubhab Mukherjee, et al.
ACS Biomaterials Science & Engineering (2019) Vol. 6, Iss. 1, pp. 167-181
Closed Access | Times Cited: 42
Is the Neutrophil-to-Lymphocyte Ratio a Useful Prognostic Indicator in Melanoma Patients?
Joshua T. Cohen, Thomas J. Miner, Michael P. Vezeridis
Melanoma Management (2020) Vol. 7, Iss. 3
Open Access | Times Cited: 37
Melatonin as a Repurposed Drug for Melanoma Treatment
Rachana Pathipaka, Anita Thyagarajan, Ravi P. Sahu
Medical Sciences (2023) Vol. 11, Iss. 1, pp. 9-9
Open Access | Times Cited: 11
Targeting ERK beyond the boundaries of the kinase active site in melanoma
Rachel M. Sammons, Ranajeet Ghose, Kenneth Y. Tsai, et al.
Molecular Carcinogenesis (2019) Vol. 58, Iss. 9, pp. 1551-1570
Open Access | Times Cited: 31
Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review
Austin Greco, Danish Safi, Umang Swami, et al.
Cancers (2019) Vol. 11, Iss. 12, pp. 1950-1950
Open Access | Times Cited: 30
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives
Mark R. Middleton, Christoph Höeller, Olivier Michielin, et al.
British Journal of Cancer (2020) Vol. 123, Iss. 6, pp. 885-897
Open Access | Times Cited: 30
Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches
Ion G. Motofei
Current Treatment Options in Oncology (2019) Vol. 20, Iss. 6
Closed Access | Times Cited: 28
Growth Hormone Upregulates Melanocyte-Inducing Transcription Factor Expression and Activity via JAK2-STAT5 and SRC Signaling in GH Receptor-Positive Human Melanoma
Reetobrata Basu, Prateek Kulkarni, Yanrong Qian, et al.
Cancers (2019) Vol. 11, Iss. 9, pp. 1352-1352
Open Access | Times Cited: 27
Biocompatible gum arabic-gold nanorod composite as an effective therapy for mistreated melanomas
Jenifer Pendiuk Gonçalves, Anderson Fraga da Cruz, Ábner Magalhães Nunes, et al.
International Journal of Biological Macromolecules (2021) Vol. 185, pp. 551-561
Closed Access | Times Cited: 21
Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma
Laëtitia Vercellino, Dorine de Jong, Laurent Dercle, et al.
Diagnostics (2022) Vol. 12, Iss. 5, pp. 1116-1116
Open Access | Times Cited: 14
Extracellular Vesicle-Packaged miR-195-5p Sensitizes Melanoma to Targeted Therapy with Kinase Inhibitors
Nathalia Leal Santos, Silvina Odete Bustos, Patrícia P. Reis, et al.
Cells (2023) Vol. 12, Iss. 9, pp. 1317-1317
Open Access | Times Cited: 8
Ca2+ as a therapeutic target in cancer
Scott Gross, Pranava Mallu, Hinal Joshi, et al.
Advances in cancer research (2020), pp. 233-317
Open Access | Times Cited: 23
Targeting the Hippo Pathway in Melanoma
Urszula Kazimierczak, Anna Przybyła, Marianna Smielowska, et al.
(2024)
Open Access | Times Cited: 2
Plasma lncRNA expression profile as a prognostic tool in BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor
Tomasz Kolenda, Piotr Rutkowski, Michał Michalak, et al.
Oncotarget (2019) Vol. 10, Iss. 39, pp. 3879-3893
Open Access | Times Cited: 20
BRAF RNA is prognostic and widely expressed in lung adenocarcinoma
Dávid Dóra, Imre Vörös, Zoltán Varga, et al.
Translational Lung Cancer Research (2023) Vol. 12, Iss. 1, pp. 27-41
Open Access | Times Cited: 6
Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta‐analysis and systematic review
Qingliang Yu, Jiayi Xie, Jiangmiao Li, et al.
Cancer Medicine (2019) Vol. 8, Iss. 12, pp. 5414-5424
Open Access | Times Cited: 18
Synthetic Approaches to New Drugs Approved during 2018
Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 19, pp. 10652-10704
Closed Access | Times Cited: 16
Page 1 - Next Page

Scroll to top